CytomX Therapeutics 2024 revenue $138.1M (up 36% YoY); CX-2051 data expected 1H 2025; headcount cut 40%

CytomX Therapeutics, Inc.

Revenue $138.1M for FY2024 vs $101.2M in FY2023 (+36%); cash and investments $100.6M vs $174.5M at year-end.
Lead program CX-2051 (EpCAM ADC) Phase 1a initial data in advanced CRC expected 1H 2025; dose escalation at 7th dose level.
CX-801 (IFN-alpha) Phase 1a translational data in melanoma expected 2H 2025; monotherapy dose exceeds approved peginterferon dose.
CX-904 (EGFR-CD3 TCE) development discontinued by mutual decision with Amgen.
January 2025 restructuring reduced headcount ~40% to extend cash runway into Q2 2026; Astellas milestone triggered $5M payment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.